Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial

Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. IBR854 Injection is a universal off-the-shelf CAR-raNK cell product derived from allogeneic peripheral blood. The indication is the treatment of patients with unresectable locally advanced or metastatic solid tumors who currently have no or cannot tolerate standard treatment. It is the first non-gene-modified CAR-raNK cell therapy for solid tumors in China, and the world's first FIC (First in class) products.

Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end.

Medicilon cell immunotherapy drug service platform
Enabling the sustainable development of global cellular immunotherapy

Cellular immunotherapy is currently known as the most promising treatment for cancer. In recent years, China's cell therapy industry is booming, and the advent of innovative drugs represented by CAR-T cell therapy has endowed immune cell therapy with more potential.

Medicilon, as a one-stop biopharmaceutical preclinical comprehensive R&D service CRO in China, has always been at the forefront of advanced technology, and has built a one-stop research platform for the preclinical R&D of cellular immunotherapy drugs. Using a wealth of animal models and a variety of advanced analytical techniques, Medicilon could provide pharmacodynamic research, drug safety evaluation, and pharmacokinetic research for a variety of immunotherapeutic drugs including CAR-T, TCR-T, and CAR-NK, bioanalysis and other R&D services. Medicilon has completed several preclinical development projects of immunotherapy programs for clients worldwide.

The clinical approval of IBR854 injection means that China's NK cell therapy industry has taken a further step forward, which strongly proves the advantages and innovation capabilities of iMBioRay’s CAR-raNK cell technology platform, as well as the R&D service strength of Medicilon’s cell immunotherapy drug platform. Both parties accumulated valuable experience to develop more cellular immunotherapy drugs in the future.

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Shanghai Medicilon Inc.

搜索此博客